Why EXACT Sciences Corporation (NASDAQ: EXAS) stock is under pressure

Free $100 Forex No-Deposit Bonus

EXACT Sciences Corporation (NASDAQ: EXAS) stock fell 13.67% on January 13th, 2020 (Source: Google finance) after the finished the $2.8 billion acquisition deal of California’s Genomic Health. Exact Sciences Corp. expects the estimated combined revenue earned by both companies for the recent fourth quarter to be in between $294 million and $296 million

As per the preliminary, unaudited earnings from the Cologuard take-home colon cancer test maker. Screening revenue is expected to be in the range of $229-230M, an increase of 61 percent from 2018, and Precision Oncology revenue is expected to be in the range of $65-66M for period Nov. 8, 2019 through Dec. 31, 2019. The company expects Precision Oncology proforma revenue for full fourth quarter to be in the range of $118-119M, which reflects an increase of 13 percent from 2018

Exact Sciences is projecting to report 477,000 completed Cologuard tests for the quarter, which is a 63% increase when compared with the year-ago quarter. Oncotype DX test volume is expected to be 41,000, which is an increase of 14 percent For the 12-month period ending Dec. 31, 2019, the company expects the revenue to be in between $874.5 million and $876.5 million and full-year Cologuard test volume to be of 1.68 million, which is an increase of 80% compared to 2018.

Further after the combination with Genomic Health, the company now has the leading scientific minds, an experienced commercial team with deep relationships, and the global footprint necessary to underpin the growth of current and future cancer diagnostics. The combined companies had projected to generate revenue in the range of about $1.6 billion in 2020 and have a commercial presence in more than 90 countries with a cancer test portfolio that reaches across primary care, oncology, OB/GYN, gastroenterology and urology, Exact Sciences previously reported. Exact Sciences had also previously stated Cologuard has a total available U.S. screening market of $15 billion, with an additional $3 billion opportunity among people ages 45-49, while Genomic’s Oncotype DX portfolio of products, which offer screening tests for breast, colon and prostate cancer, has a total available market of $2 billion.

Meanwhile, the company had delivered the revenue of $218.8 million and had screened about 456,000 people with Cologuard during the third quarter ended September 30, 2019. Third-quarter 2019 revenue and test volume both had posted the growth of 85 percent and 89 percent, respectively, from the same period of 2018.

Copyright © 2020. All Rights Reserved. FXDailyReport.Com
Risk Warning: Trading CFDs is a high risk activity and you may lose more than your initial deposit. You should never invest money that you cannot afford to lose. FXDailyReport.com will not accept any liability for loss or damage as a result of reliance on the information contained within this website including data, quotes, charts and buy/sell signals. Please be fully informed regarding the risks and costs associated with trading the financial markets.